Drug intelligence / Profile preview

UP1007

Development stage: Preclinical
Lead developer: UPPthera
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

UP1007 is a small molecule targeted protein degrader (TPD) being developed by UPPthera for the treatment of central nervous system (CNS) and immune-mediated diseases. The drug is designed to selectively target and induce the degradation of an undisclosed inflammation-related protein by leveraging the ubiquitin-proteasome system. By eliminating the pathogenic protein rather than simply inhibiting its activity, UP1007 aims to provide a more robust therapeutic response in neuro-inflammatory and autoimmune conditions. As of early 2024, the program is in the lead optimization stage of preclinical development.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)

Beyond the preview

Go deeper on UP1007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UP1007.

Explore the full profile